MS Research Spotlight: Transcranial Therapy for Fatigue, Lemtrada Good News, and More
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The MultipleSclerosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Rossi K. Transcranial Stimulation at Home Reduces Fatigue in Multiple Sclerosis. MD Magazine. https://www.mdmag.com/medical-news/transcranial-stimulation-at-home-reduces-fatigue-multiple-sclerosis. Published January 3, 2019. Accessed January 23, 2019.
- Farooq I. Correcting minority underrepresentation in MS clinical trials - EPR. European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/news/82591/minority-representation-clinical/. Published January 2, 2019. Accessed January 23, 2019.
- Han-soo L. SNUH finds cause for chronic relapsing inflammatory optic neuropathy. Korea Biomedical Review. http://www.koreabiomed.com/news/articleView.html?idxno=4851. Published January 2, 2019. Accessed January 23, 2019.
- Jacobs S. Infratentorial Lesions Beneficial for Differentiating Fabry Disease vs MS. Neurology Advisor. https://www.neurologyadvisor.com/multiple-sclerosis/infratentorial-lesion-presence-differentiates-fabry-disease-from-multiple-sclerosis/article/823870/. Published January 2, 2019. Accessed January 23, 2019.
- Jacobs S. Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis. Neurology Advisor. https://www.neurologyadvisor.com/multiple-sclerosis/no-evidence-of-disease-activity-neda-3-and-disability-improvement-with-alemtuzumab-ms/article/823868/. Published January 1, 2019. Accessed January 23, 2019.